BETHESDA, Maryland-The first large, multicenter study to compare digital vs standard film mammography has begun enrolling patients. The Digital Mammographic Imaging Screening Trial (DMIST) will study 49,500 women at 18 centers in the United States and one center in Canada.
A study that evaluated 76 patients, aged 48 to 62 years, who underwent prostate brachytherapy between 1995 and 1999 using either palladium-103 or iodine-125 seed implants, reported that more than 98% achieved 5-year survival.
Interdisciplinary Research to Be Focus of Case Institute
SAN FRANCISCO-While bone mineral density decreases with ovarian ablation via the leutinizing hormone releasing hormone (LHRH) analog goserelin (Zoladex), the loss is partly recovered within a year after 2 years of treatment. Also, the loss may be minimized by the addition of tamoxifen (Nolvadex), according to an analysis of ZIPP (Zoladex in Premenopausal Patients) trial data presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 96).
SAN FRANCISCO-Adding vitamin B12 and folic acid to chemotherapy with pemetrexed disodium (Alimta) reduces the incidence of severe life-threatening toxicities, according to research presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 300).
SEATTLE-Radiology practices that are converting to digital systems should be alert to the possibility of overuse syndromes, based on the experience of the radiology department at Tripler Army Medical Center, Honolulu. Lynne Ruess, MD, chief of pediatric radiology at Tripler, reported her department’s experience at the 101st Annual Meeting of the American Roentgen Ray Society (abstract 175).
Neuropathic pain may be defined as pain related to abnormal somatosensory processing in either the peripheral or central nervous system. This pathophysiologic label is typically applied when the painful symptom is associated
Clinical trials of agents to prevent cancer in populations at risk are relatively recent. To date, these consist of a few large population-based studies. Trials in this area focus on the prevention of cancer in individuals with specific predetermined risk
Neuropathic pain may be defined as pain related to abnormal somatosensory processing in either the peripheral or central nervous system. This pathophysiologic label is typically applied when the painful symptom is associated
Pressure ulcers are a common problem, with about 1.5 to 3 million individuals in the United Stated affected. Treatment may be costly, requiring lengthy periods of hospitalization. Central to the development of pressure
In this article (the first of a two-part interview), Benjamin Djulbegovic, MD, PhD, discusses the uncertainty principle in clinical trials, a subject he has written about in The Lancet and elsewhere. Dr. Djulbegovic is associate professor of medicine, Divisions of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa.
Anemia is a frequent complication of cancer and its associated treatment. Although its occurrence is well documented in the chemotherapy setting, the prevalence and nature of anemia in the radiation oncology setting
Anemia is a frequent complication of cancer and its associated treatment. Although its occurrence is well documented in the chemotherapy setting, the prevalence and nature of anemia in the radiation oncology setting
Anemia is a frequent complication of cancer and its associated treatment. Although its occurrence is well documented in the chemotherapy setting, the prevalence and nature of anemia in the radiation oncology setting
SAN FRANCISCO-Radioimmunotherapy (RIT) with the investigational radiolabeled monoclonal antibody known as Bexxar (tositumomab and iodine I-131 tositumomab) is effective and well tolerated in non-Hodgkin’s lymphoma (NHL) patients with poor prognostic features, according to retrospective analyses presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO).
BETHESDA, Maryland-The Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended that the Food and Drug Administration approve the marketing of Zevalin (ibritumomab tiuxetan, IDEC Pharmaceuticals) for the treatment of patients with rituximab (Rituxan)-refractory follicular, B-cell non-Hodgkin’s lymphoma (NHL).
ROCKVILLE, Maryland-The emerging science of protein analysis called proteomics is being applied directly to the care of cancer patients in a joint research and clinical program of the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). Proteomics is the study of the body’s proteins and how they function and interact.
In this time-honored series, the editors have assembled a panel of internationally recognized experts and accomplished a "tour de force" in presenting an overview of the past year’s most salient discoveries in cancer research. They have chosen
As if the prospective Medicare cuts in payments for outpatient chemotherapy drugs were not troubling enough, there is another dark Medicare cloud. The American Medical Association (AMA) is predicting that Medicare may also cut physician
NEW YORK-More than 500 cancer patients across the country participated in a Cancer Care, Inc. teleconference addressing a little-discussed concern literally on the mind of many chemotherapy patients: forgetfulness during and after chemotherapy.
NEW YORK-The persistence of fatigue for up to a year after cancer treatment is a common and debilitating occurrence. Participants in a Cancer Care, Inc. teleconference were given information on the causes of cancer-related fatigue and strategies for coping with it.
BETHESDA, Maryland-Richard D. Klausner, MD, has resigned as director of the National Cancer Institute to become president of a new scientific organization, the Case Institute for Health, Science and Technology. In a letter to President George W. Bush, Dr. Klausner called his 6-year tenure "the most challenging and rewarding of my career. The NCI is a jewel that I have had the honor to lead."
TORONTO, Canada-The combination of positron emission tomography (PET) and computed tomography (CT) has proved particularly advantageous in the diagnosis and treatment of cancer of the head and neck, Carolyn Cidis Meltzer, MD, said at the 48th Annual Meeting of the Society of Nuclear Medicine (abstract 133).
NEW ORLEANS-Diffusion-weighted MRI reveals rapid changes in tumor water diffusion values after successful therapeutic intervention in solid tumors. It therefore appears capable of predicting treatment response within days of initiating therapy, Brian D. Ross, PhD, of the University of Michigan, said at the 92nd Annual Meeting of the American Association for Cancer Research (AACR).
SAN FRANCISCO-Aberrant responses to growth signals lead to the development of several types of cancer. The mammalian target of rapamycin (mTOR) is a protein kinase involved in the signal transduction pathway that links growth stimuli and cell cycle progression. It has emerged as a promising new target for intervening in the cancer process.
SAN FRANCISCO-HIV-positive patients with non-Hodgkin’s lymphoma (NHL) should not be excluded from chemotherapy or given a limited-dose regimen, Joseph Sparano, MD, said at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 1172).
RESEARCH TRIANGLE PARK, North Carolina-Sixteen chemicals and other agents will undergo toxicologic review by the National Toxicology Program for possible listing as known or reasonably anticipated to be human carcinogens in the 11th edition of the federal Report on Carcinogens.
WASHINGTON-Mastectomy does not improve either survival or local control when patients present with axillary node metastases and an occult primary tumor, Georges Vlastos, MD, of Geneva University Hospital, Geneva, Switzerland, said at the 54th Annual Cancer Symposium of the Society of Surgical Oncology. He described a retrospective study of 45 women with this rare condition, conducted when he was at M. D. Anderson Cancer Center.
SAN FRANCISCO-Five years of tamoxifen (Nolvadex) is standard treatment for many women with estrogen-receptor (ER)-sensitive breast cancer, but the question of what to do after that is unresolved. Raloxifene (Evista) has been considered by some researchers as a possible next treatment, but preclinical data suggest this will not be a successful strategy. Ruth M. O’Regan, MD, of Northwestern University Robert H. Lurie Comprehensive Cancer Center, presented the data at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 95).
WASHINGTON-More than beauty lies in the eye of the beholder. For example, the National Conference of State Legislatures (NCSL) and the Campaign for Tobacco Free Kids offered quite different interpretations of a report released by NCSL at its annual meeting.